Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

医学 临床试验 医学物理学 淋巴瘤 可比性 淋巴结 实体瘤疗效评价标准 肿瘤科 内科学 放射科 临床研究阶段 数学 组合数学
作者
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,Joseph M. Connors,Tim Lister,Julie M. Vose,Antonio J Grillo-López,Anton Hagenbeek,Fernando Cabanillas,Donald Klippensten,Wolfgang Hiddemann,Ronald A. Castellino,Nancy L. Harris,Jamés O. Armitage,William Carter,Richard T. Hoppe,George P. Canellos
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:17 (4): 1244-1244 被引量:3286
标识
DOI:10.1200/jco.1999.17.4.1244
摘要

ABSTRACT: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter by computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients—especially those with large-cell NHL—who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval by regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
浮空鱼完成签到,获得积分10
2秒前
2秒前
edsenone发布了新的文献求助10
4秒前
qpzn发布了新的文献求助10
5秒前
阿离完成签到,获得积分10
5秒前
6秒前
coco发布了新的文献求助10
6秒前
7秒前
7秒前
xy完成签到,获得积分10
7秒前
稳重代容发布了新的文献求助10
8秒前
eyyan完成签到,获得积分10
9秒前
10秒前
11秒前
CAAA发布了新的文献求助10
11秒前
dlwlrma关注了科研通微信公众号
12秒前
WuYujie完成签到,获得积分10
12秒前
12秒前
ding应助BK采纳,获得10
13秒前
酷酷的初兰完成签到,获得积分20
13秒前
尘封的记忆完成签到,获得积分10
14秒前
15秒前
18秒前
小蘑菇应助闲闲美如炭采纳,获得10
19秒前
WuYujie发布了新的文献求助10
20秒前
20秒前
爆米花应助GH采纳,获得10
21秒前
22秒前
22秒前
8R60d8应助JasonSun采纳,获得10
22秒前
CAAA完成签到,获得积分20
25秒前
26秒前
有魅力听枫完成签到,获得积分10
27秒前
dlwlrma发布了新的文献求助10
27秒前
风中雨双发布了新的文献求助30
27秒前
28秒前
高高建辉完成签到 ,获得积分10
29秒前
谁家那小谁完成签到,获得积分10
29秒前
ma完成签到 ,获得积分20
31秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
《粉体与多孔固体材料的吸附原理、方法及应用》(需要中文翻译版,化学工业出版社,陈建,周力,王奋英等译) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3084504
求助须知:如何正确求助?哪些是违规求助? 2737517
关于积分的说明 7545573
捐赠科研通 2387170
什么是DOI,文献DOI怎么找? 1265830
科研通“疑难数据库(出版商)”最低求助积分说明 613169
版权声明 598336